Insilico Medicine
Executive Summary
Insilico Medicine is a pioneering AI-driven drug discovery company that achieved the industry milestone of advancing the first AI-discovered drug (INS018_055) into Phase II trials for idiopathic pulmonary fibrosis. The company raised a record-breaking $787M pre-IPO round in March 2026 under the Earendil Labs brand, positioning for a potential US IPO. With clear BIOSECURE status and Hong Kong/Shanghai operations, Insilico represents a lower-risk opportunity for US pharma partnerships in the AI drug discovery space. The company appears deal-ready given its advanced pipeline and recent fundraising success.
Structure: Insilico operates with dual headquarters in Hong Kong and Shanghai, suggesting a typical Greater China biotech structure with Hong Kong serving as the international hub. The company has rebranded as Earendil Labs for IPO purposes, indicating preparation for US capital markets listing. Specific VIE or holding company structures are not disclosed and would require due diligence verification.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Alex Zhavoronkov | Founder & CEO | PhD, Moscow State University; Johns Hopkins postdoc |
Ownership & Shareholder Structure
Corporate Events
Insilico raises $787M pre-IPO
Insilico Medicine (branded as Earendil Labs for IPO purposes) raised $787M ahead of potential US IPO. Largest pre-IPO round for an AI drug discovery company. Lead asset INS018_055 (anti-fibrotic) in Phase II.
Clinical Trials(9 total)
3
Phase 2
6
Phase 1
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06724042 | ISM5939, Cisplatin, Docetaxel, Pembrolizumab | Ph.1 | NOT YET RECRUITING | 159 |
| NCT07265570 | ISM5411 tablets, ISM5411 tablets, ISM5411 tablets, Placebo | Ph.2 | RECRUITING | 80 |
| NCT06414460 | ISM3412 | Ph.1 | RECRUITING | 80 |
| NCT06566079 | ISM6331 | Ph.1 | RECRUITING | 100 |
| NCT06445517 | ISM8207 | Ph.1 | RECRUITING | 60 |
| NCT05975983 | INS018_055, Placebo | Ph.2 | RECRUITING | 40 |
| NCT06012578 | ISM5411, Placebo | Ph.1 | COMPLETED | 79 |
| NCT05938920 | INS018_055, Placebo | Ph.2 | COMPLETED | 71 |
| NCT05154240 | INS018_055, Placebo | Ph.1 | COMPLETED | 78 |
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating no current regulatory restrictions for US partnerships
Key Exposures:
- •Shanghai operations may involve some mainland China data processing
- •Potential future policy changes affecting AI/biotech sector
Mitigation: Hong Kong headquarters provides regulatory buffer; IPO preparation suggests strong compliance framework
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific out-licensing deals mentioned, but $787M pre-IPO raise indicates strong investor validation and potential partnership readiness
Approach: Approach as high-priority target for AI drug discovery partnerships or platform licensing deals. Company's IPO preparation suggests openness to strategic partnerships to strengthen pre-public profile.
Red Flags
- ⚠Limited disclosure on corporate structure details
- ⚠Dual China/Hong Kong operations may complicate due diligence
- ⚠IPO timeline uncertainty could affect partnership priorities
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 9
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (9 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.